Transitioning from preclinical development into first-in-human is one of the most critical and complex stages in drug development. Early strategic decisions can have a significant impact on timelines, regulatory interactions, study success, and overall programme progression.

Join Dr Jon Sisson, Executive Medical Director, Clinical Development and Regulatory Strategy, and Christopher Floyd, SVP, Head of Clinical and Medical and Head of Neuroscience, as they answer your questions and share practical insights on the key considerations for successful early clinical development.

In this 45-minute session, you'll gain practical insights into:
● Early regulatory strategy and planning for clinical entry
● Key considerations in first-in-human study design
● Critical decision points before initiating clinical development
● Common pitfalls that can delay programmes and how to avoid them

Plus, you'll have the opportunity to ask your questions live or submit them in advance.

Submit your questions in advance: [email protected]